We have some exciting news to share! The Motley Fool UK has now become The Twelfth Magpie -- an independent, UK-owned company, led by our long-serving UK management team — Mark Rogers, Chris Nials and Heather Adlington. In practical terms, it’s the same team you know, now fully focused on serving our UK readers and members.

Just as importantly, our approach remains unchanged: long-term, jargon-free, and on your side. This site is our new home, and there will be extra tweaks made across the coming few days as we settle in. So if anything looks a little off, please bear with us!

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

The BT share price soars by 20%. Here’s why I think it could beat the FTSE 100

BT Group plc (LON: BT.A) could offer further growth potential versus the FTSE 100 (INDEXFTSE:UKX).

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

What a difference six months can make. That’s how long it has taken for the BT (LSE: BT.A) share price to gain 20%. And it has come at a time when the FTSE 100 has dropped significantly, with fears surrounding the prospects for the world economy holding back its performance.

Looking ahead, BT may continue to recover. It has appointed a new CEO, is delivering on its cost-reduction strategy and still appears to have a low valuation. Here’s why it could continue to outperform the FTSE 100 alongside another stock that released a positive update on Thursday.

XXX

Improving prospects

The company in question is multinational pharmaceutical group Hikma (LSE: HIK). It released a trading update having delivered strong performance since the start of the financial year. It has raised its guidance for the full year, delivering revenue and profit growth which is ahead of its expectations. Both its Generics and Injectables businesses are performing well, while in the MENA region, its Branded business is continuing to grow steadily. It is continuing to benefit from new product launches, as well as a diversified product range.

Alongside its trading update, the company also released news of a partnership with Vectura. It will develop and commercialise the company’s Open, Inhale, Close (OIC) dry product inhaler platform. With the generic respiratory market being a key growth area for Hikma, this could lead to improving prospects over the long term.

While the stock has a price-to-earnings (P/E) ratio of around 23, it seems to offer growth potential due to its improving financial prospects. Having gained 105% in the last year, the stock could post further capital growth.

Recovery potential

As mentioned, the BT share price has enjoyed a very positive six-month period. Its recent update showed that it has started to implement an aggressive strategy change which has seen 2,000 roles made redundant already. Further job cuts are ahead and, while they are painful for those involved, they could create a stronger business over the medium term.

The company has also announced the appointment of a new CEO. Although there is a risk that he will seek to make major changes and this could cause instability, the progress that is seemingly being made as a new strategy is delivered may mean that the company is in a stronger position by the start of 2019.

Despite its 20% rise in the last six months, BT continues to have a price-to-earnings (P/E) ratio of 9. This indicates that it may still be trading at a discount to its intrinsic value, which could suggest there is more scope for growth. Although it may have been one of the FTSE 100’s more disappointing shares in previous years, a new strategy and new management team could catalyse the company’s future performance. While uncertainty remains, it has the potential to keep beating the FTSE 100.

Peter Stephens owns shares of Hikma Pharmaceuticals. The Motley Fool UK has recommended Hikma Pharmaceuticals. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Friends and sisters exploring the outdoors together in Cornwall. They are standing with their arms around each other at the coast.
Investing Articles

£503 buys 14 shares in this FTSE 250 stock that returned 23.9% annually for the last 15 years

This FTSE 250 stock has averaged a huge return for 15 years. At today's price, £503 buys 14 shares. But…

Read more »

Black woman using loudspeaker to be heard
Investing Articles

£1,000 buys 25 shares in this FTSE 100 stock that’s returned 29.2% annually for the last 10 years

This FTSE 100 mining stock has returned close to 30% a year for a decade. At 3,995p, £1,000 buys 25…

Read more »

Female student sitting at the steps and using laptop
Investing Articles

Down 47%, is this growth stock finally worth buying in May?

With a £288m order book and a hidden pipeline of defence and nuclear contracts, is this growth stock now too…

Read more »

House models and one with REIT - standing for real estate investment trust - written on it.
Investing Articles

2 REITs yielding 7%+ to consider for passive income in 2026

A REIT backed by the NHS and another backed by Tesco and Sainsbury's with both yielding 7%+. Here's why I'm…

Read more »

Woman riding her old fashioned bicycle along the Beach Esplanade at Aberdeen, Scotland.
Investing Articles

Just 97 shares of this UK dividend stock generate £238 in passive income

A 5.7% yield, £238 in passive income from just 97 shares, and one of the most divisive dividend stocks on…

Read more »

ISA coins
Investing Articles

£10,000 in an ISA generates a second income of…

The London Stock Exchange is home to some of the world's most generous dividends. But how big a second income…

Read more »

Shot of a senior man drinking coffee and looking thoughtfully out of a window
Investing Articles

Expert recommendations: 2 top income stocks yielding 7%+!

With yields of 7.2% and 7.8% respectively, these two income stocks are catching the eyes of institutional analysts. Should investors…

Read more »

Illustration of flames over a black background
Investing Articles

3 top income-focused stocks to buy in May 2026, according to experts

Looking for a stock to buy for income in May 2026? Experts have flagged these three UK dividend shares as…

Read more »